Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Type I endometrial cancer is a common tumor of the female genital tract. Since in post-menopausal women aromatase enzyme can stimulate the endometrial tissue neoplastic growth, the use of aromatase inhibitors may have a therapeutic effect, especially in patients not eligible for surgery. Methods: A systematic review has been performed, with a very specific scope, i.e., the use of aromatase inhibitors in the treatment of advanced or recurrent endometrial cancer, as a single agent or in combination with others drugs. Results: On the basis of the 117 records retrieved from the bibliographic search, the rationale for the use of aromatase inhibitors in endometrial cancer therapy is discussed. Six papers fall within the scope of our systematic review and their results are thoroughly analyzed. Moreover, we report our experience on the clinical effectiveness of anastrozole in the post-chemotherapy treatment of a patient affected by advanced-stage endometrial cancer. Conclusion: In general, aromatase inhibitors seem to have limited clinical benefit in the treatment of advanced and recurrent endometrial cancer, although further clinical trials are necessary to investigate more in depth their role. In our case, we experienced a positive feedback in terms of control of an advanced-stage disease.

Original languageEnglish
Pages (from-to)701-8
Number of pages8
JournalArchives of Gynecology and Obstetrics
Volume293
Issue number4
DOIs
Publication statusPublished - Apr 2016

Fingerprint

Aromatase Inhibitors
Endometrial Neoplasms
Adenocarcinoma
Therapeutics
Aromatase
Therapeutic Uses
Clinical Trials
Drug Therapy
Enzymes
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Adenocarcinoma
  • Anastrozole
  • Aromatase inhibitor
  • Endometrial cancer
  • Hormone therapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{362f14c1cd6d449c9c62c50ec0b2f967,
title = "Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma",
abstract = "Purpose: Type I endometrial cancer is a common tumor of the female genital tract. Since in post-menopausal women aromatase enzyme can stimulate the endometrial tissue neoplastic growth, the use of aromatase inhibitors may have a therapeutic effect, especially in patients not eligible for surgery. Methods: A systematic review has been performed, with a very specific scope, i.e., the use of aromatase inhibitors in the treatment of advanced or recurrent endometrial cancer, as a single agent or in combination with others drugs. Results: On the basis of the 117 records retrieved from the bibliographic search, the rationale for the use of aromatase inhibitors in endometrial cancer therapy is discussed. Six papers fall within the scope of our systematic review and their results are thoroughly analyzed. Moreover, we report our experience on the clinical effectiveness of anastrozole in the post-chemotherapy treatment of a patient affected by advanced-stage endometrial cancer. Conclusion: In general, aromatase inhibitors seem to have limited clinical benefit in the treatment of advanced and recurrent endometrial cancer, although further clinical trials are necessary to investigate more in depth their role. In our case, we experienced a positive feedback in terms of control of an advanced-stage disease.",
keywords = "Adenocarcinoma, Anastrozole, Aromatase inhibitor, Endometrial cancer, Hormone therapy",
author = "Stefano Bogliolo and Barbara Gardella and Mattia Dominoni and Valentina Musacchi and Chiara Cassani and Francesca Zanellini and {de Silvestri}, Annalisa and Gaggero, {Chiara Roberta} and Luciana Babilonti and Arsenio Spinillo",
year = "2016",
month = "4",
doi = "10.1007/s00404-015-3974-9",
language = "English",
volume = "293",
pages = "701--8",
journal = "Archives of Gynecology",
issn = "0170-9925",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma

AU - Bogliolo, Stefano

AU - Gardella, Barbara

AU - Dominoni, Mattia

AU - Musacchi, Valentina

AU - Cassani, Chiara

AU - Zanellini, Francesca

AU - de Silvestri, Annalisa

AU - Gaggero, Chiara Roberta

AU - Babilonti, Luciana

AU - Spinillo, Arsenio

PY - 2016/4

Y1 - 2016/4

N2 - Purpose: Type I endometrial cancer is a common tumor of the female genital tract. Since in post-menopausal women aromatase enzyme can stimulate the endometrial tissue neoplastic growth, the use of aromatase inhibitors may have a therapeutic effect, especially in patients not eligible for surgery. Methods: A systematic review has been performed, with a very specific scope, i.e., the use of aromatase inhibitors in the treatment of advanced or recurrent endometrial cancer, as a single agent or in combination with others drugs. Results: On the basis of the 117 records retrieved from the bibliographic search, the rationale for the use of aromatase inhibitors in endometrial cancer therapy is discussed. Six papers fall within the scope of our systematic review and their results are thoroughly analyzed. Moreover, we report our experience on the clinical effectiveness of anastrozole in the post-chemotherapy treatment of a patient affected by advanced-stage endometrial cancer. Conclusion: In general, aromatase inhibitors seem to have limited clinical benefit in the treatment of advanced and recurrent endometrial cancer, although further clinical trials are necessary to investigate more in depth their role. In our case, we experienced a positive feedback in terms of control of an advanced-stage disease.

AB - Purpose: Type I endometrial cancer is a common tumor of the female genital tract. Since in post-menopausal women aromatase enzyme can stimulate the endometrial tissue neoplastic growth, the use of aromatase inhibitors may have a therapeutic effect, especially in patients not eligible for surgery. Methods: A systematic review has been performed, with a very specific scope, i.e., the use of aromatase inhibitors in the treatment of advanced or recurrent endometrial cancer, as a single agent or in combination with others drugs. Results: On the basis of the 117 records retrieved from the bibliographic search, the rationale for the use of aromatase inhibitors in endometrial cancer therapy is discussed. Six papers fall within the scope of our systematic review and their results are thoroughly analyzed. Moreover, we report our experience on the clinical effectiveness of anastrozole in the post-chemotherapy treatment of a patient affected by advanced-stage endometrial cancer. Conclusion: In general, aromatase inhibitors seem to have limited clinical benefit in the treatment of advanced and recurrent endometrial cancer, although further clinical trials are necessary to investigate more in depth their role. In our case, we experienced a positive feedback in terms of control of an advanced-stage disease.

KW - Adenocarcinoma

KW - Anastrozole

KW - Aromatase inhibitor

KW - Endometrial cancer

KW - Hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=84949960581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949960581&partnerID=8YFLogxK

U2 - 10.1007/s00404-015-3974-9

DO - 10.1007/s00404-015-3974-9

M3 - Article

C2 - 26671487

AN - SCOPUS:84949960581

VL - 293

SP - 701

EP - 708

JO - Archives of Gynecology

JF - Archives of Gynecology

SN - 0170-9925

IS - 4

ER -